| Study characteristics |
| Methods |
To explore the influence from Drug Advisory Commitee members’ financial conflicts of interest on the meeting recommendations. FDA Oncologic Drugs Advisory Committee meetings between January 2000 and December 2004 |
| Data |
79 advisory committee reports (82 advisory committee reports included in the study, but not all had data available in a format for inclusion in analysis) |
| Comparisons |
Advisory committee reports with financial conflicts of interest (defined as at least one committee members with investments, employment, consultancy, advisory capacity, research funding, speakers’ bureau activities, or lectures) and advisory committee reports without financial conflicts of interest |
| Outcomes |
Recommendations (favourable recommendations defined as votes in favour of drug approval) |
| Funding source |
Funding source not described |
| Declaration of conflicts of interest |
The authors disclosed no conflicts of interest related to any for‐profit organisation |
| Notes |
|
| Risk of bias |
| Item |
Authors' judgement |
Support for judgement |
| Adequate document inclusion process |
No |
Only one author assessed advisory committee reports for inclusion (according to personal correspondence with corresponding author) |
| Adequate coding of conflicts of interest |
Yes |
One author coded each committee member, and another author verified all data |
| Adequate coding of recommendations |
Yes |
One author coded the recommendations of each advisory committee report, and another author verified all data |
| Adequate dealing with confounding |
No |
Compared advisory committee reports of different oncology drugs |
